Clinical Trials
26 trialsManagement of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)
Sir Mortimer B. Davis - Jewish General Hospital
PICASSO
St Vincent's Hospital, Sydney
DIVINE
Mayo Clinic
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
National Cancer Center Hospital East
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Swiss Cancer Institute
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
Icahn School of Medicine at Mount Sinai
ANDARP
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
University of California, Davis
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)
Dana-Farber Cancer Institute
ExBAT
Latin American Cooperative Oncology Group
INTREPId (INTermediate Risk Erection PreservatIon Trial)
Brigham and Women's Hospital
Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019
Peking University First Hospital
ARACOG
Alliance Foundation Trials, LLC.
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
Vanderbilt-Ingram Cancer Center
DECREASE
Trans Tasman Radiation Oncology Group
ODENZA
Gustave Roussy, Cancer Campus, Grand Paris
Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer
Xijing Hospital
DAROTAXEL
Erasmus Medical Center
ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.
Swiss Cancer Institute
DART
University Hospital, Ghent
SChLAP/IDC
University Health Network, Toronto
A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer
D'Or Institute for Research and Education
Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
START
UNICANCER